Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
16-18 March, 2026
Food Ingredients Chin... Food Ingredients China
Not Confirmed
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Not Confirmed
Not Confirmed
17-19 March, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
BePharma
Not Confirmed
Contact SupplierBePharma
Industry Trade Show
Not Confirmed
16-18 March, 2026
Food Ingredients Chin... Food Ingredients China
Industry Trade Show
Not Confirmed
17-19 March, 2026
Rare Disease SummitRare Disease Summit
Industry Trade Show
Not Confirmed
17-19 March, 2026
Digital content
NEWS #PharmaBuzz
26 Feb 2026
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/accent-halts-solid-tumor-trial-over-adverse-events-pivots-other-lead-cancer-program
28 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260128013399/en/Accent-Therapeutics-to-Utilize-Inocras-CancerVision-and-MRDVision-Platforms-in-Phase-12-ATX-295-Clinical-Study
22 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/accent-therapeutics-presents-new-preclinical-data-on-lead-clinical-programs-atx-295-and-atx-559-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-302589136.html
08 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/boehringer-ingelheim-obtains-novel-preclinical-oncology-program-from-accent-therapeutics-302576299.html
22 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/accent-therapeutics-announces-trial-in-progress-poster-for-first-in-human-study-of-atx-559-at-2025-asco-annual-meeting-302461098.html
28 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/accent-therapeutics-presents-data-supporting-therapeutic-potential-of-first-in-class-dhx9-inhibitor-atx-559-and-novel-kif18a-inhibitor-atx-295-at-the-aacr-annual-meeting-2025-302438756.html
Drugs in Development
Details:
Through the acquisition, Boehringer Ingelheim for a preclinical, potentially first-in-class small molecule program.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 08, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Acquisition
Boehringer Ingelheim Obtains Novel Preclinical Oncology Program from Accent Therapeutics
Details : Through the acquisition, Boehringer Ingelheim for a preclinical, potentially first-in-class small molecule program.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 08, 2025
Details:
ATX-295, is a potential best-in-class inhibitor for KIF18A, being investigated for the treatment of adult patients with advanced/metastatic platinum-resistant or refractory ovarian cancer.
Lead Product(s): ATX-295
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 15, 2025
Lead Product(s) : ATX-295
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Accent Doses First Patient and gets FDA Fast Track for ATX-295 and ATX-559
Details : ATX-295, is a potential best-in-class inhibitor for KIF18A, being investigated for the treatment of adult patients with advanced/metastatic platinum-resistant or refractory ovarian cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 15, 2025
Details:
ATX-295 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): ATX-295
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 29, 2025
Details : ATX-295 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 29, 2025
Details:
ATX-559 is a first-in-class oral DHX9 inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of advanced solid tumors.
Lead Product(s): ATX-559
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 24, 2024
Lead Product(s) : ATX-559
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Accent Announces IND Clearance for ATX-559, A DHX9 Inhibitor
Details : ATX-559 is a first-in-class oral DHX9 inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of advanced solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 24, 2024
Details:
ATX-559 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): ATX-559
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 03, 2024
Details : ATX-559 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 03, 2024
Details:
The net proceeds will support Accent's first-in-class DHX9 inhibitor for triple-negative breast cancer and ovarian cancer, alongside a potentially best-in-class KIF18A inhibitor.
Lead Product(s): ATX-968
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Miscellaneous
Sponsor: Bristol Myers Squibb
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing January 23, 2024
Lead Product(s) : ATX-968
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : $75.0 million
Deal Type : Series C Financing
Accent Therapeutics Raises $75 Million Series C for Precision Cancer Therapies
Details : The net proceeds will support Accent's first-in-class DHX9 inhibitor for triple-negative breast cancer and ovarian cancer, alongside a potentially best-in-class KIF18A inhibitor.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 23, 2024
Details:
The presentation will describe the first identification of potent and selective small molecule inhibitors of DHX9 that demonstrate tumor cell killing in both in vitro and in vivo preclinical cancer models.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The presentation will describe the first identification of potent and selective small molecule inhibitors of DHX9 that demonstrate tumor cell killing in both in vitro and in vivo preclinical cancer models.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 06, 2023
Details:
This collaboration combines Accent’s expertise in RMP-targeting therapeutics with Ipsen’s capabilities and proven track record in Oncology medicine development and commercialization.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: Ipsen
Deal Size: $446.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration October 18, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Ipsen
Deal Size : $446.0 million
Deal Type : Collaboration
Details : This collaboration combines Accent’s expertise in RMP-targeting therapeutics with Ipsen’s capabilities and proven track record in Oncology medicine development and commercialization.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 18, 2021
Details:
Proceeds from the financing will be used to advance the development of Accent’s novel therapies targeting RNA-modifying proteins (RMPs), including its lead programs METTL3 and ADAR1.
Lead Product(s): METTL3
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: EcoR1 Capital
Deal Size: $63.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 23, 2020
Lead Product(s) : METTL3
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : EcoR1 Capital
Deal Size : $63.0 million
Deal Type : Series B Financing
Accent Therapeutics nabs $63M for RNA cancer push
Details : Proceeds from the financing will be used to advance the development of Accent’s novel therapies targeting RNA-modifying proteins (RMPs), including its lead programs METTL3 and ADAR1.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
